Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: Design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors

被引:18
作者
Ghosh, Arun K. [1 ,2 ]
Chapsal, Bruno D. [1 ,2 ]
Steffey, Melinda [1 ,2 ]
Agniswamy, Johnson [3 ]
Wang, Yuan-Fang [3 ]
Amano, Masayuki [4 ,5 ]
Weber, Irene T. [3 ]
Mitsuya, Hiroaki [4 ,5 ,6 ]
机构
[1] Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA
[2] Purdue Univ, Dept Med Chem, W Lafayette, IN 47907 USA
[3] Georgia State Univ, Dept Biol, Atlanta, GA 30303 USA
[4] Kumamoto Univ, Dept Hematol, Grad Sch Med & Pharmaceut Sci, Kumamoto 8608556, Japan
[5] Kumamoto Univ, Dept Infect Dis, Grad Sch Med & Pharmaceut Sci, Kumamoto 8608556, Japan
[6] NCI, Expt Retrovirol Sect, HIV & AIDS Malignancy Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
HIV-1 protease inhibitors; P2; ligand; Drug resistance; Design and synthesis; X-ray crystal structure; DRUG-RESISTANT MUTANTS; BIOLOGICAL EVALUATION; P2-LIGANDS; BACKBONE;
D O I
10.1016/j.bmcl.2012.01.061
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The design, synthesis, and biological evaluation of novel C3-substituted cyclopentyltetrahydrofuranyl (Cp-THF)-derived HIV-1 protease inhibitors are described. Various C3-functional groups on the Cp-THF ligand were investigated in order to maximize the ligand-binding site interactions in the flap region of the protease. Inhibitors 3c and 3d have displayed the most potent enzyme inhibitory and antiviral activity. Both inhibitors have maintained impressive activity against a panel of multidrug resistant HIV-1 variants. A high-resolution X-ray crystal structure of 3c-bound HIV-1 protease revealed a number of important molecular insights into the ligand-binding site interactions. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2308 / 2311
页数:4
相关论文
共 50 条
  • [31] Design and Synthesis of Potent HIV-1 Protease Inhibitors Incorporating Hexahydrofuropyranol-Derived High Affinity P2 Ligands: Structure-Activity Studies and Biological Evaluation
    Ghosh, Arun K.
    Chapsal, Bruno D.
    Baldridge, Abigail
    Steffey, Melinda P.
    Walters, D. Eric
    Koh, Yasuhiro
    Amano, Masayuki
    Mitsuya, Hiroaki
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (02) : 622 - 634
  • [32] Design, Synthesis, and Biological Evaluation of Darunavir Analogs as HIV-1 Protease Inhibitors
    Rehman, Muhammad Asad Ur
    Chuntakaruk, Hathaichanok
    Amphan, Soraat
    Suroengrit, Aphinya
    Hengphasatporn, Kowit
    Shigeta, Yasuteru
    Rungrotmongkol, Thanyada
    Krusong, Kuakarun
    Boonyasuppayakorn, Siwaporn
    Aonbangkhen, Chanat
    Khotavivattana, Tanatorn
    ACS BIO & MED CHEM AU, 2024, 4 (05): : 242 - 256
  • [33] Design and Development of Highly Potent HIV-1 Protease Inhibitors with a Crown-Like Oxotricyclic Core as the P2-Ligand To Combat Multidrug-Resistant HIV Variants
    Ghosh, Arun K.
    Rao, Kalapala Venkateswara
    Nyalapatla, Prasanth R.
    Osswald, Heather L.
    Martyr, Cuthbert D.
    Aoki, Manabu
    Hayashi, Hironori
    Agniswamy, Johnson
    Wang, Yuan-Fang
    Bulut, Haydar
    Das, Debananda
    Weber, Irene T.
    Mitsuya, Hiroaki
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (10) : 4267 - 4278
  • [34] Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1′ ligand
    Dou, Yue
    Zhu, Mei
    Dong, Biao
    Wang, Ju-Xian
    Zhang, Guo-Ning
    Zhang, Fan
    Wang, Yu-Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 30 (07)
  • [35] Novel HIV-1 Protease Inhibitors (PIs) Containing a Bicyclic P2 Functional Moiety, Tetrahydropyrano-Tetrahydrofuran, That Are Potent against Multi-PI-Resistant HIV-1 Variants
    Ide, Kazuhiko
    Aoki, Manabu
    Amano, Masayuki
    Koh, Yasuhiro
    Yedidi, Ravikiran S.
    Das, Debananda
    Leschenko, Sofiya
    Chapsal, Bruno
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (04) : 1717 - 1727
  • [36] Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants
    Ma, Ling
    Wen, Jiajia
    Dong, Biao
    Zhou, Jinming
    Hu, Shangjiu
    Wang, Juxian
    Wang, Yucheng
    Zhu, Mei
    Cen, Shan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
  • [37] Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands
    Yang, Zhi-Heng
    Bai, Xiao-Guang
    Zhou, Lei
    Wang, Ju-Xian
    Liu, Hong-Tao
    Wang, Yu-Cheng
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (09) : 1880 - 1883
  • [38] Evaluation of darunavir-derived HIV-1 protease inhibitors incorporating P2? amide-derivatives: Synthesis, biological evaluation and structural studies
    Ghosh, Arun K.
    Shahabi, Dana
    Kipfmiller, Maya
    Ghosh, Ajay K.
    Johnson, Megan
    Wang, Yuan -Fang
    Agniswamy, Johnson
    Amano, Masayuki
    Weber, Irene T.
    Mitsuya, Hiroaki
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2023, 83
  • [39] Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors
    Babu, S. N. Narendra
    Rangappa, K. S.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (02) : 874 - 880
  • [40] Design and Synthesis of Novel N-Hydroxy-Dihydronaphthyridinones as Potent and Orally Bioavailable HIV-1 Integrase Inhibitors
    Johnson, Ted W.
    Tanis, Steven P.
    Butler, Scott L.
    Dalvie, Deepak
    DeLisle, Dorothy M.
    Dress, Klaus R.
    Flahive, Erik J.
    Hu, Qiyue
    Kuehler, Jon E.
    Kuki, Atsuo
    Liu, Wen
    McClellan, Guy A.
    Peng, Qinghai
    Plewe, Michael B.
    Richardson, Paul F.
    Smith, Graham L.
    Solowiej, Jim
    Tran, Khanh T.
    Wang, Hai
    Yu, Xiaoming
    Zhang, Junhu
    Zhu, Huichun
    JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (09) : 3393 - 3417